This event will be held online via webinar. You will receive the webinar link after you register.
This seminar will provide an update on efforts to eliminate hepatitis C infection among people who inject drugs, including interventions that have been effective to enhance HCV testing, linkage to treatment and care.
The availability of direct-acting antiviral therapies for the treatment of hepatitis C infection have been a game-changer, stimulating a global movement to meet targets set forth by the World Health Organization to eliminate hepatitis C infection as a major global health threat. This seminar will provide an overview of progress towards hepatitis C elimination among people who inject drugs, including strategies to enhance hepatitis C testing, linkage to care, and treatment.
Jason Grebely is a Professor in the Viral Hepatitis Clinical Program at the Kirby Institute in the Faculty of Medicine at UNSW Sydney in Australia.
Professor Grebely’s research focuses on the epidemiology, natural history and therapeutic strategies for acute and chronic HCV infection in people who inject drugs. He has published over 260 peer-reviewed publications and has current research funding from Australia’s National Health and Medical Research Council and the US National Institutes of Health.
He is a Senior Editor for the International Journal of Drug Policy. He is also the President of the International Network for Hepatitis in Substance Users, an international body for improving knowledge translation, education and advocacy for HCV among people who inject drugs.